Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.
Radioimmunotherapy based on α-particle emitters has excellent properties as a treatment against micrometastatic and disseminated cancers because of the short path length (50 - 80 μm) and high linear energy transfer (∼ 100 keV/ μm). Alpha-particles produce clustered DNA double-strand breaks and highly reactive hydroxyl radicals when hitting biological tissue. Hence, targeted α-particle therapy offers the potential of selective tumor cell killing with low damage to surrounding normal tissue. The ideal applications for targeted α-therapy are in treating neoplastic cells in circulation or when cancer cells are present as free-floating cells or spread along compartment walls. This review will provide a brief overview of the most promising radionuclides for targeted α-therapy and compare their relative biological effectiveness (RBE) and normal tissue toxicity.
Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310 Oslo, Norway. jostein.dahle@rr-research.no
Jostein
J
Dahle
Nasir
N
Abbas
Øyvind S
ØS
Bruland
Roy H
RH
Larsen
D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use* / Q000633:toxicity*; D009369:Neoplasms / Q000532:radiotherapy*; D012062:Relative Biological Effectiveness
D018796:Immunoconjugates